⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314438 | 0.86 | APLNR (0.34) | — | |
| SCHEMBL19568015 | 0.82 | KMT2A (0.31) | — | |
| SCHEMBL8319326 | 0.76 | JAK2 (0.31) | — | |
| SCHEMBL31673337 | 0.76 | — | — | |
| SCHEMBL24197645 | 0.76 | JAK2 (0.33) | — | |
| SCHEMBL365047 | 0.76 | — | — | |
| SCHEMBL2162286 | 0.76 | JAK2 (0.33) | — | |
| SCHEMBL13907209 | 0.76 | JAK2 (0.33) | — | |
| SCHEMBL2306469 | 0.75 | — | — | |
| Bromide SCHEMBL30923588 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368092-A1 | 2,4-Dihydro-3H-1,2,4-Triazol-3-One P2X7 Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-11-07 | — | — | US | disclosed |
| EP-4396181-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | Breye Therapeutics ApS (DK) | 2024-07-10 | — | — | EP | disclosed |
| CN-117881675-A | 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists | 布雷耶疗法有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| WO-2023031319-A1 | 2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE P2X7 ANTAGONISTS | AXXAM S.P.A. (IT) | 2023-03-09 | — | — | WO | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| EP-3398941-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2018-11-07 | — | — | EP | disclosed |
| EP-2024349-B1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20150231141-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-20110086855-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875639-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101925300-A | Novel compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB | 2010-12-22 | — | — | CN | disclosed |
| EP-2222165-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| CN-101448800-A | Novel compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB (US) | 2009-06-03 | — | — | CN | disclosed |
| WO-2009067613-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-2024349-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
| WO-2007140439-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |